Latest Period
Q4 2025
Security Snapshot
Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE) Institutional Ownership
CUSIP: 578784100
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
143
Shares (Excl. Options)
48,370,362
Price
$41.43
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- MAZE on Nasdaq
- Shares outstanding
- 50,017,820
- Price per share
- $27.42
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 48,370,362
- Total reported value
- $2,003,833,352
- % of total 13F portfolios
- 0.02%
- Share change
- +4,663,462
- Value change
- +$199,439,391
- Number of holders
- 143
- Price from insider filings
- $27.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- MAZE - Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 578784100.
- 143 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 143 to 21 between Q4 2025 and Q1 2026.
- Reported value moved from $2,003,833,352 to $19,444,990.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 143 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 578784100?
CUSIP 578784100 identifies MAZE - Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 578784100:
Significant Owners of Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 9.3% | -33% | $179,808,372 | -$64,304,000 | 4,473,958 | -26% | Third Rock Ventures IV, L.P. | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 9% | +16% | $174,515,671 | +$39,762,017 | 4,342,266 | +30% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| ARCH Venture Fund X, L.P. | 9.4% | $36,215,266 | 4,120,053 | ARCH Venture Fund X, L.P. | 31 Mar 2025 | |||
| Deep Track Capital, LP | 9% | +30% | $59,431,096 | +$13,927,661 | 3,948,910 | +31% | Deep Track Capital, LP | 30 Jun 2025 |
| JANUS HENDERSON GROUP PLC | 7.3% | +22% | $83,143,819 | +$15,075,261 | 3,206,472 | +22% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| Paradigm Biocapital Advisors LP | 6.1% | $155,788,502 | 3,051,087 | Paradigm BioCapital Advisors LP | 25 Mar 2026 | |||
| Matrix Capital Management Company, LP | 3.5% | -37% | $42,880,026 | -$21,586,725 | 1,653,684 | -33% | Matrix Capital Management Company, LP | 30 Sep 2025 |
| GV 2019, L.P. | 2.9% | -52% | $57,528,994 | -$42,419,680 | 1,388,583 | -42% | Alphabet Holdings LLC | 31 Dec 2025 |
| Foresite Capital Fund IV, L.P. | 1.4% | -70% | $15,790,022 | -$47,922,789 | 608,948 | -75% | James Tananbaum | 30 Sep 2025 |
As of 31 Dec 2025, 143 institutional investors reported holding 48,370,362 shares of Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE). This represents 97% of the company’s total 50,017,820 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 9.1% | 4,567,274 | 0% | 5.1% | $189,222,162 |
| TRV GP IV, LLC | 8.9% | 4,473,958 | -26% | 73% | $185,356,080 |
| Deep Track Capital, LP | 8.5% | 4,246,440 | +7.5% | 4% | $175,930,009 |
| ARCH Venture Management, LLC | 8.2% | 4,120,053 | 0% | 26% | $170,693,796 |
| JANUS HENDERSON GROUP PLC | 6.3% | 3,142,587 | +318% | 0.06% | $130,197,379 |
| BlackRock, Inc. | 4.6% | 2,287,155 | +74% | 0% | $94,756,831 |
| a16z Capital Management, L.L.C. | 3.4% | 1,702,225 | 0% | 4.5% | $70,523,182 |
| VANGUARD GROUP INC | 3.4% | 1,697,015 | +27% | 0% | $70,307,332 |
| VR ADVISER, LLC | 3.1% | 1,548,569 | +26% | 3.2% | $64,157,214 |
| Alphabet Inc. | 2.8% | 1,388,583 | -42% | 2.2% | $57,528,994 |
| General Catalyst Group Management, LLC | 2.1% | 1,035,910 | 0% | 19% | $42,917,751 |
| Woodline Partners LP | 2.1% | 1,035,229 | 0% | 0.17% | $42,889,537 |
| TRV GP V, LLC | 1.9% | 950,800 | 0% | 9.2% | $39,391,644 |
| Logos Global Management LP | 1.9% | 950,000 | -23% | 2.6% | $39,358,500 |
| Bellevue Group AG | 1.8% | 887,708 | 0.7% | $36,777,742 | |
| MARSHALL WACE, LLP | 1.7% | 847,472 | +9% | 0.03% | $35,110,765 |
| ArrowMark Colorado Holdings LLC | 1.5% | 767,383 | +41% | 0.7% | $31,792,678 |
| Casdin Capital, LLC | 1.5% | 758,857 | 0% | 2% | $31,439,446 |
| FMR LLC | 1.5% | 728,605 | +11% | 0% | $30,186,105 |
| Ikarian Capital, LLC | 1.3% | 644,680 | -13% | 3.5% | $26,709,093 |
| Caligan Partners LP | 1.1% | 550,191 | 2.1% | $22,794,413 | |
| STATE STREET CORP | 1.1% | 533,005 | +39% | 0% | $22,082,397 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 527,281 | +11% | 0% | $21,850,329 |
| Foresite Capital Management IV, LLC | 1% | 522,657 | 0% | 9.4% | $21,653,680 |
| Squadron Capital Management LLC | 0.98% | 490,000 | 0% | 9.1% | $20,300,700 |
Institutional Holders of Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 651,433 | $19,444,990 | +$14,795,757 | $29.85 | 21 |
| 2025 Q4 | 48,370,362 | $2,003,833,352 | +$199,439,391 | $41.43 | 143 |
| 2025 Q3 | 42,970,633 | $1,114,223,528 | +$108,250,260 | $25.93 | 93 |
| 2025 Q2 | 38,836,437 | $476,719,891 | -$14,337,293 | $12.27 | 74 |
| 2025 Q1 | 40,038,674 | $441,393,439 | +$441,263,796 | $11.01 | 68 |